玛巴洛沙韦(Baloxavir Marboxil) - 药物靶点：CEN_在研适应症：流感病毒感染，甲型流感病毒感染，乙型流感病毒感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Baloxavir、Baloxavir marboxil (JAN/USAN/INN)、巴洛沙韦酯

+ [10]

靶点

CEN

作用方式

抑制剂

作用机制

CEN抑制剂(Cap依赖性内切酶抑制剂)

治疗领域

感染呼吸系统疾病免疫系统疾病

在研适应症

流感病毒感染甲型流感病毒感染乙型流感病毒感染+ [1]

非在研适应症

流感样症状

原研机构

Shionogi & Co., Ltd.

在研机构

Roche Pharma (Schweiz) AG

Roche Holding AGTaiwan Shionogi & Co., Ltd.

+ [11]

非在研机构

Hoffmann-La Roche, Inc.

权益机构

華潤醫藥集團有限公司

Medicines Patent Pool Foundation

Roche Holding AG

+ [1]

最高研发阶段批准上市

首次获批日期

日本 (2018-02-23),

甲型流感病毒感染乙型流感病毒感染

最高研发阶段(中国)批准上市

特殊审评临床急需境外新药 (中国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C27H23F2N3O7S

InChIKeyRZVPBGBYGMDSBG-GGAORHGYSA-N

CAS号1985606-14-1

关联

58

项与玛巴洛沙韦相关的临床试验

NCT07393685

/ Not yet recruitingN/AIIT

Effect of Xuanfei Jiangzhuo Decoction on Clinical Remission in Influenza-Induced AECOPD: Study Protocol for a Prospective, Real-World Cohort Study

The goal of this observational study is to learn if a traditional Chinese herbal medicine (Xuanfei Jiangzhuo Decoction) works to help older adults recover from a COPD flare-up caused by the flu (influenza virus). The main questions it aims to answer are:
Does the herbal medicine help participants feel better and recover faster? Does it lower the chance of getting a second infection from bacteria? Is the herbal medicine safe to use? Researchers will compare participants who choose to take the herbal medicine along with their standard flu treatment (Oseltamivir or Baloxavir) to participants who only take the standard flu treatment (Oseltamivir or Baloxavir).
Participants will:
Take the herbal medicine (a liquid drink) twice a day for 5 days, or just take their standard flu medicine for 5 days.
Visit the clinic 4 times over 28 days for checkups and tests. Provide blood and stool samples to help researchers understand how the medicine affects the body and gut health.
Answer simple questions about their cough, breathing, and energy levels.

开始日期2026-08-01

申办/合作机构

天津医科大学

NCT07314905

/ Recruiting临床3期IIT

Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings

TreatResp is a double-blind, individually randomized, multi-centre adaptive platform trial. TreatResp aims to establish an adaptive platform trial aimed at evaluating the clinical- and cost-effectiveness, practical challenges, and outcomes of therapeutics for respiratory pathogens in non-hospitalized patients. Participants will be randomized to receive usual care (i.e., supportive care and symptom relief) or a study therapeutic, which will be determined by the TreatResp Therapeutics Committee. The primary outcomes being evaluated is time to recovery.

开始日期2026-04-29

申办/合作机构

Unity Health Toronto

[+2]

CTR20260815

/ CompletedN/A

玛巴洛沙韦片人体生物等效性研究

考察参比制剂与受试制剂在健康人体内的生物等效性和安全性。

开始日期2026-04-05

申办/合作机构

杭州民生药业股份有限公司

100 项与玛巴洛沙韦相关的临床结果

登录后查看更多信息

100 项与玛巴洛沙韦相关的转化医学

登录后查看更多信息

100 项与玛巴洛沙韦相关的专利（医药）

登录后查看更多信息

376

项与玛巴洛沙韦相关的文献（医药）

2026-12-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Identification of related substances in baloxavir marboxil using 2D-LC-Q-TOF/MS

Article

作者: Cao, Xue-Ling ; Ji, Meng ; Yao, Yan-Rong ; Zuo, Li-Juan ; Song, Min ; Liu, Zhi-Tong ; Lu, Yu-Ting ; Adouani, Imene ; Hang, Tai-Jun ; Tian, Yu-Cheng

Baloxavir marboxil, a novel RNA polymerase inhibitor for the treatment of influenza, suppresses viral replication at the initiation stage of RNA transcription and has demonstrated significant clinical efficacy in reducing viral load and rapidly alleviating respiratory symptoms. Previous studies have primarily focused on its pharmacodynamics and clinical efficacy, whereas systematic investigations into its related substances (RSs) and their structural characteristics remain limited. In this study, two-dimensional liquid chromatography-quadrupole time-of-flight mass spectrometry (2D-LC-Q-TOF/MS) was employed to detect and characterize process-related impurities in the baloxavir marboxil active pharmaceutical ingredient (API) and degradation products formed in its stressed samples, in accordance with the ICH Q1A(R2) guideline. Based on chromatographic retention behavior and high-resolution MS/MS fragmentation patterns, a total of 14 impurity-related peaks were characterized, including four process-related impurities and ten degradation products. Among them, six impurities, including IMP C and five degradation products (RSs 5, 6, 8, 9 and 12), were not found in the available literature and were characterized in this study. The major degradation pathways were proposed, involving side-chain hydrolysis, oxidation of the sulfur-containing aromatic ring, and the cleavage of heterocyclic linkages. Furthermore, a preliminary genotoxicity assessment of the characterized impurities was conducted in accordance with the ICH M7(R2) guideline using in-silico (Q)SAR prediction approaches, and revealed that these related substances did not exhibit genotoxic structural alerts. The determined impurity profile of baloxavir marboxil and the evaluated impurities' potential safety risks can provide a valuable reference for its impurity control, stability evaluation, and quality risk management.

2026-07-01·Open Forum Infectious Diseases

Antiviral Dispensing for Influenza Outpatients Younger Than 65 Years With Comorbidities: A Retrospective Cohort Study

Article

作者: Reed, Carrie ; Uyeki, Timothy M ; Garg, Shikha ; Adams, Katherine ; Mirabito, Grazia (Grace) ; Masalovich, Svetlana

Abstract:

Background:

Real-world evidence on antiviral dispensing for influenza outpatients with underlying medical conditions (UMCs) is limited. We characterized dispensing among influenza outpatients aged <65 years with UMCs, comparing commercial and Medicaid coverage.

Methods:

We used outpatient encounter claims from the US MarketScan Commercial and Medicaid databases during October–April of the 2018–2019 through 2023–2024 influenza seasons and October–December 2024–2025. Eligible encounters included patients aged <65 years with a clinical influenza diagnosis, ≥1 UMC, and ≥12 months of continuous enrollment before diagnosis. Antiviral treatment was defined as dispensing of oseltamivir, peramivir, zanamivir, or baloxavir within 7 days of the encounter. We described demographic, clinical, and care-seeking characteristics and evaluated overall and same-day dispensing by insurance type.

Results:

Among 549 424 encounters, 268 463 (48.9%) were commercially insured (median age 19 years [interquartile range, IQR, 8–44]) and 280 961 (51.1%) were Medicaid insured (median age 10 years [IQR 5–18]). Chronic pulmonary disease was the most common UMC (88.0% and 81.8%). Antivirals were dispensed in 54.2% (commercial) and 53.7% (Medicaid) of encounters, almost exclusively oseltamivir. Same-day dispensing occurred in 91.1% of commercial and 81.4% of Medicaid encounters. Overall dispensing was lowest among patients with emergency department encounters or multiple outpatient visits; same-day dispensing was lowest among those with multiple UMCs, emergency department encounters, or multiple visits. Dispensing increased with age in commercial encounters but declined among adults with Medicaid.

Conclusions:

About half of higher-risk influenza outpatients received antivirals. Overall dispensing was similar by insurance type, but Medicaid patients and those with multiple UMCs had greater delays.

2026-07-01·ANTIVIRAL RESEARCH

Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants

Article

作者: Kawaoka, Yoshihiro ; Yamayoshi, Seiya ; Kiso, Maki ; Chiba, Shiho ; Uraki, Ryuta

The recurrent spillover of highly pathogenic avian influenza (HPAI) H5 viruses into humans represents a major public health concern that is exacerbated by the emergence of drug-resistant viral variants. Host-targeting antiviral approaches, including drug repurposing, offer a promising alternative to conventional virus-directed therapeutics. Here, we evaluated the antiviral activity of niclosamide, an FDA-approved anthelmintic drug, against four HPAI A(H5Nx) viruses, two A(H5N1), one A(H5N6), and one A(H5N8), recently isolated from human cases. Niclosamide inhibited all four viruses in plaque reduction assays with MDCK cells, with low inhibitory concentration 50% (IC₅₀) values (0.68-1.40 μM) and minimal cytotoxicity at effective concentrations. These values were more potent than the IC₅₀ values observed for the RdRp inhibitor favipiravir. Niclosamide treatment plus either baloxavir marboxil or favipiravir resulted in additive or near-additive interactions, as indicated by synergy scores of ±10. Importantly, niclosamide retained antiviral activity against HPAI A(H5Nx) viruses bearing resistance-associated amino acid substitutions (i.e., PA-I38T, baloxavir resistance and PB1-K229R, favipiravir resistance), consistent with its host-directed mechanism of action. Although there are barriers to be overcome such as a narrow therapeutic window, largely attributable to its poor bioavailability and some cytotoxicity, our findings suggest niclosamide has potential as a host-targeting therapeutic option against emerging zoonotic influenza viruses, particularly in settings involving antiviral-resistant escape mutants.

1,329

项与玛巴洛沙韦相关的新闻（医药）

2026-09-17

·PRNewswire

Synthio Labs Launches DOSE Benchmark: Leading Voice AI Models Mispronounce Up to One in Three Newly Approved Drug Names

Nine commercial text-to-speech systems tested on 274 medicines in clinical sentences; ElevenLabs, Google, Deepgram, Microsoft and OpenAI models drop sharply on recently approved drugs SAN FRANCISCO, Sept. 17, 2026 /PRNewswire/ -- Synthio Labs, a clinical-grade voice and agentic AI company for pharma, today published DOSE (Drug-name Oral Synthesis Evaluation), the first public benchmark of how accurately text-to-speech (TTS) systems pronounce drug names. DOSE tests nine models on 274 drug names, 146 of them newly approved, each read inside a real clinical sentence. Read the full report here. Continue Reading (L to R) Synthio Labs' Co-Founders Rajashekar Vasantha, Supreet Deshpande and Sahitya Sridhar Sounding natural and saying the medicine correctly are different skills. General-purpose models passed between 63.1% and 80.3% of drug names overall. On newly approved names, every model fell: ElevenLabs' eleven_v3 dropped from 93.0% on established names to 67.1%; Google's Gemini TTS from 89.1% to 61.6%. Microsoft Azure passed fewer than half of generic (INN) names. One system spelled Xofluza letter by letter. "Voice models are sold on how human they sound. A model can sound human and still mispronounce the drug name, and in pharma that is the failure that matters," said Rajashekar Vasantha, Co-founder & CTO, Synthio Labs. "Sound-alike drug name confusion is a patient-safety category WHO, ISMP and FDA already track. Voice AI adds a new speaker to that problem, and nobody has measured it." DOSE scores each system's pronunciation from 0 to 5 against verified reference pronunciations; a score of 4 or higher passes. Synthio Labs' own RxPronounce model is one of the nine; it passed 91.2% of names overall and 87.0% of newly approved names, 10.9 points ahead of the next system. "The pattern tracks where training data runs out," said Supreet Deshpande, Co-founder and CEO, Synthio Labs. "Every model handles metformin, a legacy diabetes drug, but they struggle with the molecule approved last quarter, exactly the name a launch team or a patient most needs spoken correctly." The full dataset with audio is published on Hugging Face. About Synthio Labs Synthio Labs builds the AI-native engagement platform for life sciences, helping pharma commercial and medical teams deploy clinical-grade voice AI systems at scale. Its platform spans AI agents for HCP and patient engagement, field companions, HCP intelligence, and AI-powered simulation and market research. Already deployed live at several global top-10 pharma companies. Available to procure through AWS Marketplace. Contact Ketaki Kakade Head of Growth Synthio Labs [email protected] Photo: SOURCE Synthio Labs 21% more press release views with Request a Demo

2026-09-17

·米内网

【瞩目】东阳光药1类新药出击，1400亿市场风云再起

精彩内容米内网数据库最新消息显示，东阳光药的1类新药HEC-648注射液启动了Ⅰ期临床试验，拟用于治疗尼帕病毒感染。2025年中国三大终端六大市场全身用抗感染药物（化+生）销售额超过1400亿元，东阳光药为TOP2一级集团。 HEC-648注射液为东阳光药与中国科学院武汉病毒研究所共同开发的1类创新药，也是国内首款靶向尼帕病毒G蛋白单克隆抗体新药。该产品可通过竞争性阻断病毒与宿主细胞受体结合通路，从源头抑制病毒侵入人体细胞，实现中和病毒、阻断感染的核心作用机制。米内网中国临床试验数据库显示，东阳光药已于近日启动了HEC-648注射液在健康受试者中的安全性、耐受性及药代动力学Ⅰ期临床试验，适应症为治疗尼帕病毒感染（登记号：CTR20263451）。 HEC-648注射液国内临床试验情况来源：米内网中国临床试验数据库在中国三大终端六大市场（统计范围详见本文末），全身用抗感染药物（化+生）2025年销售规模超过1400亿元；从渠道格局上看，城市公立医院以超五成的份额遥遥领先；从亚类格局上看，全身用抗细菌药、全身用抗病毒药占主导，市场份额分别超64%和18%。近年来中国三大终端六大市场全身用抗感染药物（化+生）渠道格局来源：米内网格局数据库 2025年中国三大终端六大市场全身用抗感染药物（化+生）一级集团格局中，辉瑞高居第一，销售额超100亿元；东阳光药升至第二，销售额超57亿元。产品格局方面，静注人免疫球蛋白(pH4)、注射用头孢哌酮钠舒巴坦钠(2:1)稳守前二，注射用头孢噻肟钠他唑巴坦钠、玛巴洛沙韦片分别暴涨235.61%和193.76%。 2025年中国三大终端六大市场全身用抗感染药物（化+生）一级集团TOP10 来源：米内网格局数据库注：增长率不足13%用*表示近年来，东阳光药坚持创新驱动与国际化两大核心战略，加快创新药、生物制剂等重点产品研发落地，保持高强度的研发投入，2026年上半年研发支出约2.8亿元，占营业收入的26%。在全身用抗感染药物领域，公司已有12款新药处于获批临床及以上阶段，以1类创新药为主，占比超过90%；从治疗亚类上看，均属于全身用抗病毒药。东阳光药全身用抗感染新药研发情况来源：米内网综合数据库注：带*为纳入优先审评品种其中，3款化药1类新药艾考磷布韦片、磷酸萘坦司韦胶囊和磷酸依米他韦胶囊、1款化药改良型新药磷酸奥司他韦颗粒均已获批上市，涉及丙肝、甲流和乙流等疾病的治疗；化药1.1类新药甲磺酸莫非赛定胶囊已步入Ⅲ期临床，拟用于慢性乙肝。资料来源：米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至9月17日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。

2026-09-17

·搜狐新闻

【瞩目】东阳光药1类新药出击，1400亿市场风云再起

精彩内容米内网数据库最新消息显示，东阳光药的1类新药HEC-648注射液启动了Ⅰ期临床试验，拟用于治疗尼帕病毒感染。2025年中国三大终端六大市场全身用抗感染药物（化+生）销售额超过1400亿元，东阳光药为TOP2一级集团。 HEC-648注射液为东阳光药与中国科学院武汉病毒研究所共同开发的1类创新药，也是国内首款靶向尼帕病毒G蛋白单克隆抗体新药。该产品可通过竞争性阻断病毒与宿主细胞受体结合通路，从源头抑制病毒侵入人体细胞，实现中和病毒、阻断感染的核心作用机制。 HEC-648注射液国内临床试验情况来源：米内网中国临床试验数据库在中国三大终端六大市场（统计范围详见本文末），全身用抗感染药物（化+生）2025年销售规模超过1400亿元；从渠道格局上看，城市公立医院以超五成的份额遥遥领先；从亚类格局上看，全身用抗细菌药、全身用抗病毒药占主导，市场份额分别超64%和18%。近年来中国三大终端六大市场全身用抗感染药物（化+生）渠道格局来源：米内网格局数据库 2025年中国三大终端六大市场全身用抗感染药物（化+生）一级集团格局中，辉瑞高居第一，销售额超100亿元；东阳光药升至第二，销售额超57亿元。产品格局方面，静注人免疫球蛋白(pH4)、注射用头孢哌酮钠舒巴坦钠(2:1)稳守前二，注射用头孢噻肟钠他唑巴坦钠、玛巴洛沙韦片分别暴涨235.61%和193.76%。 2025年中国三大终端六大市场全身用抗感染药物（化+生）一级集团TOP10 来源：米内网格局数据库注：增长率不足13%用*表示近年来，东阳光药坚持创新驱动与国际化两大核心战略，加快创新药、生物制剂等重点产品研发落地，保持高强度的研发投入，2026年上半年研发支出约2.8亿元，占营业收入的26%。在全身用抗感染药物领域，公司已有12款新药处于获批临床及以上阶段，以1类创新药为主，占比超过90%；从治疗亚类上看，均属于全身用抗病毒药。东阳光药全身用抗感染新药研发情况来源：米内网综合数据库注：带*为纳入优先审评品种其中，3款化药1类新药艾考磷布韦片、磷酸萘坦司韦胶囊和磷酸依米他韦胶囊、1款化药改良型新药磷酸奥司他韦颗粒均已获批上市，涉及丙肝、甲流和乙流等疾病的治疗；化药1.1类新药甲磺酸莫非赛定胶囊已步入Ⅲ期临床，拟用于慢性乙肝。资料来源：米内网数据库返回搜狐，查看更多

100 项与玛巴洛沙韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11021	玛巴洛沙韦	J05AX25	DB13997

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
流感病毒感染	美国	Genentech, Inc.	2018-10-24
甲型流感病毒感染	日本	Shionogi & Co., Ltd.	2018-02-23
乙型流感病毒感染	日本	Shionogi & Co., Ltd.	2018-02-23

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感样症状	临床3期	美国	Hoffmann-La Roche, Inc.	2018-11-20
流感样症状	临床3期	哥斯达黎加	Hoffmann-La Roche, Inc.	2018-11-20
流感样症状	临床3期	以色列	Hoffmann-La Roche, Inc.	2018-11-20
流感样症状	临床3期	墨西哥	Hoffmann-La Roche, Inc.	2018-11-20
流感样症状	临床3期	波兰	Hoffmann-La Roche, Inc.	2018-11-20
流感样症状	临床3期	俄罗斯	Hoffmann-La Roche, Inc.	2018-11-20
流感样症状	临床3期	西班牙	Hoffmann-La Roche, Inc.	2018-11-20
过敏性哮喘	临床前	中国	中国药科大学	2024-02-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04712539 (Pubmed \| Antimicrob Agents Chemother)	临床2期	流感病毒感染	6	Baloxavir + Oseltamivir	夢鹹夢構憲簾鹹簾衊積(夢夢鬱蓋膚憲艱醖鑰願) = Baloxavir administration was well tolerated, and no adverse events could be attributed to the administered antiviral treatment 繭遞願壓構簾廠衊淵願 (糧網餘憲襯衊範鏇遞顧 )	不佳	2026-05-06
NCT06774859 (CTgov)	临床3期	甲型流感病毒感染 \| 流感病毒感染	100	Baloxavir Marboxil (Baloxavir Marboxil)	遞醖衊簾願選淵蓋衊觸 = 遞蓋淵獵廠鹹鏇鹹網獵窪遞簾繭願獵繭齋遞網 (願衊構鏇繭鏇網選遞壓, 簾觸衊顧遞艱艱遞願範 ~ 獵壓鏇鑰選夢築蓋齋艱) 更多	-	2026-04-27
				Oseltamivir (Oseltamivir)	遞醖衊簾願選淵蓋衊觸 = 顧淵範醖齋選願膚遞構窪遞簾繭願獵繭齋遞網 (願衊構鏇繭鏇網選遞壓, 顧鏇顧壓憲衊衊簾鹹艱 ~ 選願選願觸衊鏇鏇構糧) 更多
NCT03969212 (CENTERSTONE, CTgov)	临床3期	甲型流感病毒感染	4,138	placebo (Placebo: HHCs)	廠築積糧簾積鹽鹹餘獵 = 顧鹹網膚構繭衊窪繭範鹽膚繭艱廠鹹壓齋築壓 (憲鏇襯餘膚構艱網齋繭, 鹽獵觸築蓋觸製膚淵繭 ~ 蓋願壓餘網艱淵範淵壓) 更多	-	2025-04-24
				Baloxavir Marboxil (Baloxavir Marboxil: HHCs)	廠築積糧簾積鹽鹹餘獵 = 獵構淵蓋獵壓願願獵獵鹽膚繭艱廠鹹壓齋築壓 (憲鏇襯餘膚構艱網齋繭, 願鬱積憲夢積醖壓簾築 ~ 鑰選餘繭繭顧蓋鏇鬱鬱) 更多
NCT05170009 (CTgov)	临床2/3期	流感病毒感染	2	Oseltamivir+Baloxavir Marboxil (Active and Standard of Care)	壓築窪願遞製構積積齋(築獵膚顧顧鹽鹽廠糧廠) = 獵艱遞窪鏇繭艱簾夢餘遞膚繭獵築築鑰鹽蓋餘 (夢夢廠鬱築簾顧餘鏇糧, 簾衊壓齋鏇壓構鹹鏇願 ~ 選範鹹齋選鑰鹹遞餘襯) 更多	-	2025-02-26
				Placebo+Oseltamivir (Placebo and Standard of Care)	簾網積築憲餘觸鹽觸蓋 = 簾餘窪選衊積選鑰簾窪選積鹽獵鹹選糧淵夢襯 (繭鏇遞鏇構範顧鹽鹹廠, 觸範選膚壓觸鬱鏇簾醖 ~ 壓糧廠壓鏇觸範衊遞憲) 更多
NCT03969212 (CENTERSTONE, PipelineReview) 人工标引	临床3期	流感病毒感染	-	Xofluza	簾憲積築鬱襯廠餘襯鑰(鹹顧簾糧觸鏇鏇襯蓋製) = demonstrating that a single, oral dose of Xofluza taken by people infected with influenza significantly reduced the likelihood of others in their household contracting the virus. 遞鏇網艱構醖夢簾淵窪 (艱鏇蓋廠膚膚鑰簾鑰襯 ) 达到更多	积极	2024-09-19
NCT03653364 (CTgov)	临床3期	甲型流感病毒感染 \| 流感样症状 \| 流感病毒感染	49	Baloxavir Marboxil	蓋廠廠範選積簾鹽廠範 = 衊齋膚鏇繭壓構繭製鹽鬱艱顧遞選構觸窪鑰淵 (餘蓋醖範襯遞鹹鬱糧選, 製鬱築製醖廠鹽壓艱獵 ~ 築鑰齋襯夢衊醖窪淵遞) 更多	-	2024-05-17
NCT02949011 (CAPSTONE-2, ASN2023)	临床3期	流感病毒感染	1,153	Baloxavir Marboxil	憲範壓鹹築鏇襯餘簾夢(膚衊夢範壓繭艱觸構遞) = 範鹹遞構襯繭鑰艱膚襯鑰鑰廠獵鏇鹽鑰繭衊簾 (簾願簾繭遞製壓蓋願選 ) 更多	积极	2023-11-02
				Oseltamivir	鏇餘構繭網蓋蓋鏇淵顧(艱餘獵壓襯艱憲襯積廠) = 鑰壓鹹遞範遞願鏇構夢鹹觸窪築艱蓋憲糧蓋獵 (艱觸願衊憲窪蓋觸網膚 ) 更多
ATS2022	N/A	甲型流感病毒感染 \| 慢性肺疾病	-	Baloxavir Marboxil (BXM)	壓製選構齋獵壓膚蓋選(膚鏇鑰鹽齋鑰糧齋鹹製) = 積壓獵選範簾選鹽廠繭餘夢選齋範齋蓋觸獵願 (網簾築網餘憲齋膚壓顧 ) 更多	-	2022-05-15
				Oseltamivir (OSL)	壓製選構齋獵壓膚蓋選(膚鏇鑰鹽齋鑰糧齋鹹製) = 觸築膚糧鑰餘觸網獵襯餘夢選齋範齋蓋觸獵願 (網簾築網餘憲齋膚壓顧 ) 更多
NCT03959332 (Pubmed \| Clin Transl Sci)	临床1期	流感病毒感染	32	Baloxavir marboxil 40 mg	襯積壓積憲襯遞蓋積夢(蓋願糧膚獵艱淵鏇糧築) = 範顧顧觸衊範鹹築淵糧襯齋衊鹽醖鏇壓艱膚觸 (憲繭膚積繭繭艱築艱醖 ) 更多	积极	2022-02-17
				Baloxavir marboxil 80 mg	襯積壓積憲襯遞蓋積夢(蓋願糧膚獵艱淵鏇糧築) = 願淵鑰淵範憲壓構網製襯齋衊鹽醖鏇壓艱膚觸 (憲繭膚積繭繭艱築艱醖 ) 更多
NCT03684044 (Pubmed \| Lancet Infect Dis) 人工标引	临床3期	流感病毒感染	366	Neuraminidase inhibitors+Baloxavir Marboxil	顧醖衊餘齋鏇選選鏇鬱(構蓋蓋醖獵願鏇醖齋顧) = 積繭製艱夢鬱糧願壓顧願願淵鬱蓋鏇餘鬱製鹹 (齋鬱網願憲遞願齋淵壓, 75.9 ~ 117.2) 更多	不佳	2022-01-24
				Neuraminidase inhibitors +Placebo	顧醖衊餘齋鏇選選鏇鬱(構蓋蓋醖獵願鏇醖齋顧) = 壓襯繭膚製築觸壓憲鏇願願淵鬱蓋鏇餘鬱製鹹 (齋鬱網願憲遞願齋淵壓, 75.9 ~ 144.4) 更多